OMNIAB, INC. Research and Development Expense
OMNIAB, INC. (OABI) reported Research and Development Expense of $9.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- OMNIAB, INC. research and development expense for the quarter ending 2026-06-30 was $9.59M, a 11.76% decline year-over-year.
- OMNIAB, INC. research and development expense for the quarter ending 2026-03-31 was $9.64M, a 23.50% decline year-over-year.
- OMNIAB, INC. research and development expense for the quarter ending 2025-12-31 was $13.91M, a 4.53% increase year-over-year.
- OMNIAB, INC. research and development expense for the quarter ending 2025-09-30 was $10.38M, a 22.07% decline year-over-year.
- OMNIAB, INC. research and development expense for fiscal 2025 was $47.75M, a 13.35% decline from fiscal 2024.
- OMNIAB, INC. research and development expense for fiscal 2024 was $55.11M, a 2.50% decline from fiscal 2023.
- OMNIAB, INC. research and development expense for fiscal 2023 was $56.52M, a 16.87% increase from fiscal 2022.
- OMNIAB, INC. research and development expense for fiscal 2022 was $48.36M, a 23.28% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.59M 10-Q · filed 2026-08-06 | $19.23M 10-Q · filed 2026-08-06 | $33.13M derived: sum of 3 quarters · filed 2026-08-06 | $43.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.64M 10-Q · filed 2026-05-07 | $23.55M derived: sum of 2 quarters · filed 2026-05-07 | $33.93M derived: sum of 3 quarters · filed 2026-05-07 | $44.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $13.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $24.29M derived: sum of 2 quarters · filed 2026-03-04 | $35.15M derived: sum of 3 quarters · filed 2026-08-06 | $47.75M 10-K · filed 2026-03-04 |
| 2025-09-30 | $10.38M 10-Q · filed 2025-11-04 | $21.24M derived: sum of 2 quarters · filed 2026-08-06 | $33.84M 10-Q · filed 2025-11-04 | $47.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.86M 10-Q · filed 2026-08-06 | $23.47M 10-Q · filed 2026-08-06 | $36.77M derived: sum of 3 quarters · filed 2026-08-06 | $50.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $12.60M 10-Q · filed 2026-05-07 | $25.91M derived: sum of 2 quarters · filed 2026-05-07 | $39.23M derived: sum of 3 quarters · filed 2026-05-07 | $53.16M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $26.62M derived: sum of 2 quarters · filed 2026-03-04 | $40.56M derived: sum of 3 quarters · filed 2026-03-04 | $55.11M 10-K · filed 2026-03-04 |
| 2024-09-30 | $13.32M 10-Q · filed 2025-11-04 | $27.25M derived: sum of 2 quarters · filed 2025-11-04 | $41.80M 10-Q · filed 2025-11-04 | $56.57M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $13.94M 10-Q · filed 2025-08-06 | $28.49M 10-Q · filed 2025-08-06 | $43.25M derived: sum of 3 quarters · filed 2025-08-06 | $57.12M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $14.55M 10-Q · filed 2025-05-08 | $29.32M derived: sum of 2 quarters · filed 2025-05-08 | $43.18M derived: sum of 3 quarters · filed 2025-05-08 | $57.32M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $28.63M derived: sum of 2 quarters · filed 2025-03-18 | $42.77M derived: sum of 3 quarters · filed 2025-03-18 | $56.52M 10-K · filed 2025-03-18 |
| 2023-09-30 | $13.87M 10-Q · filed 2024-11-12 | $28.00M derived: sum of 2 quarters · filed 2024-11-12 | $41.76M 10-Q · filed 2024-11-12 | $54.68M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $14.13M 10-Q · filed 2024-08-08 | $27.89M 10-Q · filed 2024-08-08 | $40.81M derived: sum of 3 quarters · filed 2024-08-08 | $54.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $13.76M 10-Q · filed 2024-05-09 | $26.68M derived: sum of 2 quarters · filed 2024-05-09 | $39.87M derived: sum of 3 quarters · filed 2024-05-09 | $51.35M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $12.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $26.11M derived: sum of 2 quarters · filed 2024-03-25 | $37.59M derived: sum of 3 quarters · filed 2024-03-25 | $48.36M 10-K · filed 2024-03-25 |
| 2022-09-30 | $13.19M 10-Q · filed 2023-11-09 | $24.67M derived: sum of 2 quarters · filed 2023-11-09 | $35.45M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $11.48M 10-Q · filed 2023-08-10 | $22.26M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $10.77M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $39.23M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |